Geode Capital Management
TGTX icon

Geode Capital Management’s TG Therapeutics TGTX Stock Holding History

Geode Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200M Buy
3,642,216
+142,300
+4% +$5.82M 0.01% 804
2026
Q1 		$116M Buy
3,499,916
+96,050
+3% +$2.86M 0.01% 990
2025
Q4 		$101M Sell
3,403,866
-40,053
-1% -$1.31M 0.01% 1068
2025
Q3 		$125M Sell
3,443,919
-46,538
-1% -$1.53M 0.01% 935
2025
Q2 		$126M Buy
3,490,457
+207,890
+6% +$7.74M 0.01% 877
2025
Q1 		$129M Buy
3,282,567
+89,062
+3% +$3M 0.01% 823
2024
Q4 		$96.1M Sell
3,193,505
-11,723
-0.4% -$336K 0.01% 1029
2024
Q3 		$75M Sell
3,205,228
-1,162
-0% -$25.4K 0.01% 1187
2024
Q2 		$57.1M Buy
3,206,390
+98,946
+3% +$1.58M 0.01% 1268
2024
Q1 		$47.3M Buy
3,107,444
+10,798
+0.3% +$172K ﹤0.01% 1397
2023
Q4 		$52.9M Buy
3,096,646
+162,820
+6% +$1.89M 0.01% 1315
2023
Q3 		$24.5M Buy
2,933,826
+103,237
+4% +$1.44M ﹤0.01% 1692
2023
Q2 		$70.3M Buy
2,830,589
+150,789
+6% +$3.89M 0.01% 1010
2023
Q1 		$40.3M Buy
2,679,800
+93,527
+4% +$1.42M 0.01% 1340
2022
Q4 		$30.6M Buy
2,586,273
+175,834
+7% +$1.28M ﹤0.01% 1484
2022
Q3 		$14.3M Buy
2,410,439
+86,835
+4% +$570K ﹤0.01% 1989
2022
Q2 		$9.88M Buy
2,323,604
+135,133
+6% +$844K ﹤0.01% 2262
2022
Q1 		$20.8M Sell
2,188,471
-121,366
-5% -$1.4M ﹤0.01% 1878
2021
Q4 		$43.9M Buy
2,309,837
+7,459
+0.3% +$194K 0.01% 1400
2021
Q3 		$76.6M Buy
2,302,378
+145,702
+7% +$4.51M 0.01% 965
2021
Q2 		$83.7M Buy
2,156,676
+109,244
+5% +$4.29M 0.01% 905
2021
Q1 		$98.7M Buy
2,047,432
+269,045
+15% +$12.9M 0.02% 763
2020
Q4 		$92.5M Buy
1,778,387
+154,545
+10% +$5.22M 0.02% 733
2020
Q3 		$43.5M Buy
1,623,842
+123,295
+8% +$2.84M 0.01% 994
2020
Q2 		$29.2M Buy
1,500,547
+160,014
+12% +$2.58M 0.01% 1225
2020
Q1 		$13.2M Buy
1,340,533
+239,730
+22% +$3.03M ﹤0.01% 1565
2019
Q4 		$12.2M Sell
1,100,803
-14,542
-1% -$111K ﹤0.01% 1872
2019
Q3 		$6.26M Buy
1,115,345
+80,716
+8% +$563K ﹤0.01% 2249
2019
Q2 		$8.95M Buy
1,034,629
+106,480
+11% +$805K ﹤0.01% 2032
2019
Q1 		$7.46M Buy
928,149
+172,944
+23% +$935K ﹤0.01% 2092
2018
Q4 		$3.1M Buy
755,205
+70,398
+10% +$350K ﹤0.01% 2512
2018
Q3 		$3.83M Buy
684,807
+95,877
+16% +$1.1M ﹤0.01% 2531
2018
Q2 		$7.74M Buy
588,930
+90,679
+18% +$1.25M ﹤0.01% 2066
2018
Q1 		$7.08M Buy
498,251
+35,981
+8% +$460K ﹤0.01% 2017
2017
Q4 		$3.79M Buy
462,270
+8,699
+2% +$76K ﹤0.01% 2373
2017
Q3 		$5.37M Buy
453,571
+22,817
+5% +$260K ﹤0.01% 2165
2017
Q2 		$4.33M Buy
430,754
+68,401
+19% +$766K ﹤0.01% 2263
2017
Q1 		$4.22M Buy
362,353
+70,751
+24% +$508K ﹤0.01% 2213
2016
Q4 		$1.35M Buy
291,602
+9,477
+3% +$55.6K ﹤0.01% 2845
2016
Q3 		$2.18M Buy
282,125
+4,848
+2% +$31.2K ﹤0.01% 2512
2016
Q2 		$1.68M Buy
277,277
+158
+0.1% +$1.28K ﹤0.01% 2590
2016
Q1 		$2.36K Buy
277,119
+25,517
+10% +$223K ﹤0.01% 2347
2015
Q4 		$3M Buy
251,602
+3,986
+2% +$50.3K ﹤0.01% 2208
2015
Q3 		$2.5M Buy
247,616
+2,896
+1% +$43.1K ﹤0.01% 2289
2015
Q2 		$4.06M Buy
244,720
+51,022
+26% +$808K ﹤0.01% 2050
2015
Q1 		$3M Buy
193,698
+9,812
+5% +$149K ﹤0.01% 2177
2014
Q4 		$2.91M Buy
183,886
+7,573
+4% +$98.6K ﹤0.01% 2173
2014
Q3 		$1.88M Buy
176,313
+1,806
+1% +$16.7K ﹤0.01% 2388
2014
Q2 		$1.64M Buy
174,507
+22,340
+15% +$143K ﹤0.01% 2509
2014
Q1 		$1.05M Buy
152,167
+64,460
+73% +$382K ﹤0.01% 2768
2013
Q4 		$342K Buy
87,707
+1,103
+1% +$4.46K ﹤0.01% 3238
2013
Q3 		$441K Buy
86,604
+67,814
+361% +$415K ﹤0.01% 3009
2013
Q2 		$120K Buy
+18,790
New +$120K ﹤0.01% 3384

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management's TGTX Position: Q2 2026 in Review

Geode Capital Management increased its TG Therapeutics (TGTX) stake by 4.1% in Q2 2026, buying an estimated $5.82M and bringing the position to 3,642,216 shares worth $200M. The position accounts for 0.01% of the portfolio, ranked #804.

Geode Capital Management first reported a position in TGTX in Q2 2013 and has held it in 53 quarters since. 405 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Geode Capital Management held 3,642,216 shares of TG Therapeutics worth $200M as of Q2 2026.
  • Geode Capital Management bought 142,300 TG Therapeutics shares in Q2 2026, an estimated $5.82M.
  • TG Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #804 holding.
  • Geode Capital Management first reported a position in TG Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 405 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.